← All earnings call summaries
Sun Pharmaceutical Industries Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Q1 FY27 consolidated sales grew 10.1% y-y to INR151,836 million; EBITDA margin 28.9%
- R&D spend at 5.4% of sales; 30% on innovative medicines; Organon acquisition on track for Q4 FY27
- Management expects high single-digit revenue growth for FY27; tax rate around 27.8%
- Multiple analyst queries on specialty product ramp-up and US generics outlook; management expects sustained growth but no product-wise guidance
- India formulations sales grew 16%, market share increased to 8.5%; volume growth 5.4%
- Innovative medicines sales up 12.8% to USD351 million; driven by ILUMYA, ODOMZO, CEQUA
- US sales declined 9.7% due to generic erosion; innovative portfolio growing with Leqselvi and Unloxcyt
- Emerging markets sales up 4.2%; Rest of World flat at USD218 million
📄 Source: View original transcript (PDF)
Get Sun Pharmaceutical Industries Limited earnings summaries on Telegram
Add Sun Pharmaceutical Industries Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.